

Dr Tomas Salmonson
European Medicines Agency (EMA)
7 Westferry Circus
Canary Wharf
London
E14 4HB
United Kingdom

cc: [REDACTED] (PTL)

Munich, January 10, 2013

Withdrawal of Memantine FGK - EMEA/H/C/2687

Dear Dr Salmonson,

On behalf of the applicant FGK Representative Services GmbH I would like to inform you that, at this point of time, FGK Representative Services GmbH has taken the decision to withdraw the application for Marketing Authorisation of Memantine FGK, memantine, 7 mg, 14 mg, 21 mg, 28 mg, prolonged-release capsule, hard, which was intended to be used for the treatment of patients with moderate to severe Alzheimer's disease.

This withdrawal is based on the following reasons

- Other: Strategic reasons

There are no ongoing clinical trials or compassionate use programme. Accordingly there are no consequences of the withdrawal.

We reserve the right to make further submissions at a future date in this or other therapeutic indication(s).

Yours sincerely,

Granzer Regulatory Consulting & Services

[REDACTED]

| Senior Consultant

[REDACTED]

cc: Walter Janssens (Rapporteur)